Improvement of the production capacity of "Chemax Pharma" EOOD

The current project proposal is targeted at increasing the capacity of the existing enterprise of Chimax Pharma Ltd. in Sofia for the production of "solid dosage forms" and "powdered products" by purchasing and putting into operation of new pharmaceutical equipment: Mill for powdery materials-1pc, Powder mixer-1pc, Automatic line for primary packaging of powders for oral suspensions-1pc, Cartoning machine-1pc, Sachet machine-1pc, Automated inventory washing system -1pc. The company offers its clients high-quality pharmaceutical products, divided into three main product groups: "liquid products", "solid dosage forms" and "powdered products". With this project, the company will increase the production of the currently produced products by completing its technology park with new, high-performance machines - in the departments for preparation of active and additional substances and mixing raw materials according to the approved documentation, for "solid dosage forms" and "powdered products ". In addition, durring the secondary packaging and quality assurance departments, a major part of the manual operations now being performed will be fully automated - this will save time to implement the production cycle and will increase production capacity. This is how, the company will optimize the production process by improving its efficiency and will start to produce more from the currently produced products: "solid dosage forms" and "powdered products", thus enabling Himax Pharma Ltd. to increase production of "solid dosage forms" by over 33.1% (from 63.4 thousand to 84.5 thousand) and for "powdered products" by over 33.7% (from 2,130 million to 2,849 million pcs.). The project will be implemented in the "Industry for Healthy Life and Biotechnology" field of the Innovation Strategy for Smart Specialization.

Comments
Leave a comment

Overview

Status Closed (completion date)
Start date 22 Dec, 2020
End date 22 Dec, 2021
Contract date 22 Dec, 2020
View in UMIS

Financial information

Total cost 1,516,347.63
Grant 530,721.66
Self finance 985,625.97
Total paid 0.00
EU participation percent 85.0%

Location